For arguments sake.
Please only serious responses to this.
1.) Uplisting WILL NOT OCCUR BECAUSE FUNDAMENTALS WILL NOT BE IN PLACE FOR A LONG TIME. Does anyone understand how much it costs to uplist? Does anyone understand WHY IT IS BAD TO UPLIST? Hedge funds will short the HELL out of this stock causing the price to decline. WE DO NOT WANT TO UPLIST unless we have AT LEAST have breakeven EPS and clinical data supporting Cytosorb. Anyone who brings up the fact that we will uplist in 2014 is a joke.
2.) Break even EPS in 2014? You have to be kidding me!!! We will need $12M-$18M in annual sales before this occurs. If they do 50% QoQ growth (which is simply amazing if they can accomplish this) then by Q4 2015 they will be close to break even.
3.) FDA approval in 2014? Whattttt!!!!!! They have to do a PMA for Cytosorb AND THEN it has to go through the FDA approval process. This is going to take 1.5 to 3 years before the FDA signs off on our device.
4.) People are EXPECTING 50% QoQ increase in sales. This would be amazing if they do this, however, this is extremely hard to do. This is an exponential growth rate considering its QoQ and not YoY. I think the expectation of 50% QoQ growth in sales is a little too agressive for any company let alone CTSO. If they can accomplish this the price per share will CERTAINLY increase by a large measure if the 40M shares from the institution do not attempt to get out at $0.25.
5.) Other products contributing to sales growth? Not for a while guys. Also - we dont even have clinical data on Cytosorb for 4 years and CTSO has been pursuing that soley. What makes you think all the sudden they are going to come out with a booming study on hemodefend, etc? They have a big pipeline - however, the flagship product of this company if Cytosorb and that is where there attention should be focused - both for the company and for investors.
I think people need to understand that if this company was as much as a guarantee to get to $1+ as they think it is - then SMART MONEY would come in and buy up all of the shares to a fairly valued price. The market is extremely efficient values the market caps of company accordingly. I am telling you now, I know many investors with 20x more money than I do and people are watching this companies progress closely AND carefully. When I was at the conference the other week there was certainly a lot of interest in this stock and some decent firms were there that do thorough DD on micro-cap investments.
There is much hesitancy to value this stock at anything above $0.25 for the time being because of a few reasons:
1.) Potential selling pressure of 40M shares that are averaged at $0.25 who can purchase 20M in warrants at $0.3125 for the next 5 years.
2.) No clinical data for Cytosorb makes it hard to become adopted into medical community in the USA
3.) Uncertainty that CTSO can continue an expotential (30-50%) QoQ growth rate of Cytosorb sales
4.) Fully diluted stock is around 563M shares - which means there are 265M more shares to be issued and they have been coming out at about 1.1M shares per week added to the float
5.) In about 18 months they should be close to running out of cash (or have a few million left) which will call for another round of dilution to institutions. This could potential add another 60M shares to the float.
These 5 things are very bad if you are an investor because they will hold back appreciation of the price of your stock EVEN if the company makes progress going forward (which they 100% will).
Thoughts? Looking for educated responses only please.
